Who
Rahul Singhvi
Director
Company insider
Files Form 4 as: Director, Codexis; Director, Kairos Pharma; Director, ImmunoCellular Therapeutics; President, CEO, Novavax.
In numbers
- Trades disclosed
- 39
- Buys
- 2
- Sells
- 2
- Bought
- $3,344
- Sold
- $773K
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 17 Feb 2006
- Last trade
- 17 Jun 2026
- Last filed
- 18 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jun 2026filed 18 Jun 2026 | CDXS Codexisoption or derivative · Chemicals | SEC FORM 4 Code A | —66,350 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | CDXS Codexisoption or derivative · Chemicals | SEC FORM 4 Code A | —66,350 at $0.00 | filing |
| 8 Oct 2025filed 26 Nov 2025 | KAPA Kairos PharmaBiotechnology | SEC FORM 4 Code A | —19,084 at $0.00 | filing |
| 10 Jun 2025filed 12 Jun 2025 | CDXS CodexisChemicals | SEC FORM 4 Code A | —40,983 at $0.00 | filing |
| 11 Jun 2024filed 13 Jun 2024 | CDXS CodexisChemicals | SEC FORM 4 Code A | —30,120 at $0.00 | filing |
| 9 Nov 2023filed 14 Nov 2023 | CDXS Codexisoption or derivative · Chemicals | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 13 Jun 2023filed 15 Jun 2023 | CDXS CodexisChemicals | SEC FORM 4 Code A | —34,602 at $0.00 | filing |
| 28 Sep 2022filed 30 Sep 2022 | CDXS CodexisChemicals | SEC FORM 4 Code A | —31,347 at $0.00 | filing |
| 17 Jun 2016filed 21 Jun 2016 | ImmunoCellular Therapeuticsoption or derivative | SEC FORM 4 Code A | —156,750 at $0.00 | filing |
| 18 Sep 2015filed 22 Sep 2015 | ImmunoCellular Therapeutics | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 18 Sep 2015filed 22 Sep 2015 | ImmunoCellular Therapeuticsoption or derivative | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 26 Jun 2015filed 30 Jun 2015 | ImmunoCellular Therapeuticsoption or derivative | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 13 Jun 2014filed 17 Jun 2014 | ImmunoCellular Therapeuticsoption or derivative | SEC FORM 4 Code A | —51,154 at $0.00 | filing |
| 20 Sep 2013filed 24 Sep 2013 | ImmunoCellular Therapeuticsoption or derivative | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 24 Sep 2012filed 18 Dec 2012 | ImmunoCellular Therapeuticsoption or derivative | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 10 Mar 2011filed 14 Mar 2011 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | $625K250,000 at $2.50 | filing |
| 15 Mar 2010filed 17 Mar 2010 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 2 Jul 2009filed 6 Jul 2009 | NVAX NovavaxBiotechnology | SEC FORM 4 Sold | $150K50,000 at $3.00 | filing |
| 1 Jul 2009filed 6 Jul 2009 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code M | —150,000 at $0.00 | filing |
| 1 Jul 2009filed 6 Jul 2009 | NVAX NovavaxBiotechnology | SEC FORM 4 Code M | $111K150,000 at $0.74 | filing |
News
Head-To-Head Review: Novavax (NASDAQ:NVAX) & Alnylam Pharmaceuticals (NASDAQ:ALNY)NVAX · themarketsdaily.com · 11 Oct 2026Novavax (NASDAQ:NVAX) Sees Large Volume Increase – Should You Buy?NVAX · dailypolitical.com · 9 Oct 2026
0 headlines in the last 90 days name Rahul Singhvi; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.